References

[1] R. Morrison, T. Belz, S.K. Ihmaid, J.M.A. Al-Rawi, M.J. Angove, Dual and/or

selective DNA-PK, PI3K inhibition and isoform selectivity of some new and

known 2-amino-substituted-1,3-benzoxazines and substituted-1,3-

naphthoxazines, Med. Chem. Res. 23 (2014) 4680e4691.

[2] S.K. Ihmaid, J.M.A. Al-Rawi, C.J. Bradley, M.J. Angove, M.N. Robertson, Synthesis,

DNA-PK inhibition, antiplatelet activity studies of 2-(N-substituted-3-

aminopyridine)-substituted-1,3-benzoxazines and DNA-PK and PI3K inhibition,

homology modeling studies of 2-morpholino-(7,8-di and 8-substituted)-

1,3-benzoxazines, Eur. J. Med. Chem. 57 (2012) 85e101.

[3] K.M. Pritchard, J. Al-Rawi, C. Bradley, Synthesis, identification and antiplatelet

evaluation of 2-morpholino substituted benzoxazines, Eur. J. Med. Chem. 42

(2007) 1200e1210.

[4] S. Ihmaid, J. Al-Rawi, C. Bradley, Synthesis, structural elucidation and DNAdependent

protein kinase and antiplatelet studies of 2-amino-[5, 6, 7, 8-

mono and 7, 8-di-substituted]-1,3-benzoxazines, Eur. J. Med. Chem. 45

(2010) 4934e4946.

[5] S. Ihmaid, J. Al-Rawi, C. Bradley, M.J. Angove, M.N. Robertson, R.L. Clark,

Synthesis, structural elucidation, DNA-PK inhibition, homology modelling and

anti-platelet activity of morpholino-substituted-1,3-naphth-oxazines, Bioorg.

Med. Chem. 19 (2011) 3983e3994.

[6] G. Manning, D.B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, The protein

kinase complement of the human genome, Science (Washington, DC, U. S.)

298 (2002) 1912e1916, 1933-1934.

[7] K.M. Clapham, T. Rennison, G. Jones, F. Craven, J. Bardos, B.T. Golding,

R.J. Griffin, K. Haggerty, I.R. Hardcastle, P. Thommes, A. Ting, C. Cano, Potent

enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by

atropisomeric chromenone derivatives, Org. Biomol. Chem. 10 (2012)

6747e6757.

[8] G.C.M. Smith, S.P. Jackson, The DNA-dependent protein kinase, Genes Dev. 13
(1999) 916e934.

[9] J.J.J. Leahy, B.T. Golding, R.J. Griffin, I.R. Hardcastle, C. Richardson, L. Rigoreau,

G.C.M. Smith, Identification of a highly potent and selective DNA-dependent

protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries,

Bioorg. Med. Chem. Lett. 14 (2004) 6083e6087.

[10] I.R. Hardcastle, X. Cockcroft, N.J. Curtin, M.D. El-Murr, J.J.J. Leahy, M. Stockley,

B.T. Golding, L. Rigoreau, C. Richardson, G.C.M. Smith, R.J. Griffin, Discovery of

potent chromen-4-one inhibitors of the DNA-Dependent Protein Kinase

(DNA-PK) using a small-molecule library approach, J. Med. Chem. 48 (2005)

7829e7846.

[11] S. Radhamani, C. Bradley, T. Meehan-Andrews, S.K. Ihmaid, J. Al-Rawi, Radiosensitizing

activity of a novel benzoxazine through the promotion of

apoptosis and inhibition of DNA repair, Invest. New Drugs 32 (2014) 424e435.

[12] S. Al-Rawi, T. Meehan-Andrews, C. Bradley, J. Al-Rawi, Novel benzoxazines as

inhibitors of angiogenesis, Invest. New Drugs 33 (2015) 45e52.

[13] H. Duda, A. Ostaszynski, T. Urbanski, Halosalicylohydroxamic acids. I. Dihalosalicylohydroxamic

acids, Bull. Acad. Pol. Sci. Ser. Sci. Chim. 13 (1965)

341e347.

[14] A.N. Meldrum, M.S. Shah, The constitution of sulfosalicylic acid and of related

substances, J. Chem. Soc. Trans. 123 (1923) 1986e1993.

[15] K. Pritchard, J. Al-Rawi, A. Hughes, Generalized method for the production of

1,3-benzoxazine, 1,3-benzothiazine, and quinazoline derivatives from 2-

(Hydroxy, thio, or amino) aromatic acids using triphenylphosphine thiocyanogen,

Synth. Commun. 35 (2005) 1601e1611.

[16] M.R. Grever, S.A. Schepartz, B.A. Chabner, The National Cancer Institute:

cancer drug discovery and development program, Semin. Oncol. 19 (1992)

622e638.

[17] R.H. Shoemaker, The NCI60 human tumour cell line anticancer drug screen,

Nat. Rev. Cancer 6 (2006) 813e823.

[18] C. Cano, K. Saravanan, C. Bailey, J. Bardos, N.J. Curtin, M. Frigerio, B.T. Golding,

I.R. Hardcastle, M.G. Hummersone, K.A. Menear, D.R. Newell, C.J. Richardson,
K. Shea, G.C.M. Smith, P. Thommes, A. Ting, R.J. Griffin, 1-Substituted (dibenzo

[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with Dual

DNA-PK/PI3-K inhibitory activity, J. Med. Chem. 56 (2013) 6386e6401.

[19] C. Feng, Y. Sun, G. Ding, Z. Wu, H. Jiang, L. Wang, Q. Ding, H. Wen, PI3Kb inhibitor

TGX221 selectively inhibits renal cell carcinoma cells with both VHL

and SETD2 mutations and links multiple pathways, Sci. Rep. 5 (2015) 9465.

[20] S. Shrestha, B.R. Bhattarai, K.-H. Lee, H. Cho, Mono- and disalicylic acid derivatives:

PTP1B inhibitors as potential anti-obesity drugs, Bioorg. Med. Chem.

15 (2007) 6535e6548.

[21] J. Heppell, J. Al-Rawi, Functionalization of quinazolin-4-ones part 1: synthesis

of novel 7-substituted-2-thioxo quinazolin-4-ones from 4-substituted-2-

aminobenzoic acids and PPh3(SCN)2, J. Heterocycl. Chem. 51 (2014) 162e174.

[22] Y. Tamura, T. Kawasaki, M. Tanio, Y. Kita, Isothiocyanation of Carboxylic Acids

with the Combined Reagent, Ph3P(SCN)2: a New One-step Synthesis of 2-

thioxo-3,4-dihydro-2H-1,3-benzoxazin-4-ones and Related Compounds,

Chem. Ind., London, 1978, pp. 806e807.

[23] J.-A. Pinson, Z. Zheng, M.S. Miller, D.K. Chalmers, I.G. Jennings, P.E. Thompson,

L-Aminoacyl-triazine derivatives are isoform-selective PI3Kb inhibitors that

target nonconserved Asp862 of PI3Kb, ACS Med. Chem. Lett. 4 (2013)

206e210.

1. Sainsbury, M., 2.27 - Oxazines, Thiazines and their Benzo Derivatives A2 - Katritzky, Alan R. In
Comprehensive Heterocyclic Chemistry, Rees, C. W., Ed. Pergamon: Oxford, 1984; pp 995-1038.

2. Pritchard, K. M.; Al‐Rawi, J. M.; Hughes, A. B., Generalized Method for the Production of 1,3‐
Benzoxazine, 1,3‐Benzothiazine, and Quinazoline Derivatives from 2‐(Hydroxy, Thio, or Amino)
Aromatic Acids Using Triphenylphosphine Thiocyanogen. Synthetic Communications 2005, 35 (12),
1601-1611.

3. Finkelstein, J.; Chiang, E., Synthesis of substituted 2, 3-dihydro-4H-1, 3-benzoxazin-4-ones

and their biological activities. Journal of medicinal chemistry 1968, 11 (5), 1038-1040.
4. Rashan, L. J.; al-Rawi, J. M.; Nadir, M. T.; Awni, L., Synthesis and biological evaluation of N-
salicyloyl-N-benzyl thiourea and 2,2-dimethyl-4-oxo-6-methoxy benzo-1,3-dioxin. Farmaco 1991, 46
(5), 677-683.

5. Gammill, R.; Judge, T.; Morris, J., Preparation of antiatherosclerotic and antithrombotic 1-
benzopyran-4-ones and 2-amino-1, 3-benzoxazine-4-ones. PCT Int. Appl. WO9119707 1991.

6. Kekre, J.; Sunthankar, S., SYNTHESES AND BIOLOGICAL-ACTIVITY OF 2H-1, 3-BENZOXAZINE-2,

4 (3H)-DIONES. INDIAN JOURNAL OF CHEMISTRY 1975, 13 (12), 1275-1277.

7. Waisser, K.; Kubicová, L.; Klimešová, V.; Odlerová, Ž., New groups of potential
antituberculotics: 3-aryl-2H, 4H-benz [e][1, 3] oxazine-2, 4-diones. Comparison of the Topliss
approach with regression analysis. Collection of Czechoslovak chemical communications 1993, 58
(12), 2977-2982.

8. Kubicova, L.; Kudelova, P.; Dostal, H.; Waisser, K., Antialgal activity of 3-Phenyl-2H-1, 3-
benzoxazine-2, 4 (3H)-diones and 3-Phenyl-3H-quinazoline-4-ones against Chlorella Vulgaris. Folia
Pharm. Univ. Carol 2000, 25, 81-87.

9. Sharma, S.; Swami, M.; Sharma, R., Nitrogen Heterocyclic Analogous of Cannabinoids. Part 1.
Synthesis of 6H‐Indolo‐[1, 2‐c][1, 3] benzoxazine Systems and Evaluation of Their Biological
Activities. ChemInform 1984, 15 (29).

10. Sharma, S.; Sharma, M., Synthesis of 5H-pyrazolo [2, 3-c][1, 3] benzoxazine systems and
evaluation of their biological activities. Acta Ciencia Indica, Series Chemistry 1986, 12, 113-116.

11. Arrigoni-Martelli, E.; Conti, I., Antiinflammatory Potency of 2-(β-chloroethyl)-2, 3-dihydro-4-

oxo-6-amino-(benz-1, 3-oxazine) HCl (A 350), Phenylbutazone and Acetylsalicylic Acid in Carrageenin-
Induced Edema. Pharmacology 1964, 10 (3), 164-168.

12. Kadatz, R., Pharmakologische Eigenschaften des 2-(beta-Chloraethyl)-2, 3-dihydro-4-oxo-

(benzo-1, 3-oxazin), eines neuen Antiphlogisticum. Arzneimittelforschung 1957, 7 (11), 651-653.

13. Teotino, U.; Friz, L. P.; Gandini, A.; Bella, D. D., Thio derivatives of 2, 3-dihydro-4H-1, 3-
benzoxazin-4-one. Synthesis and pharmacological properties. Journal of medicinal chemistry 1963, 6
(3), 248-250.

14. Khalaj, A.; Abdollahi, M.; Kebriaeezadeh, A.; Adibpour, N.; Pandi, Z.; Rasoulamini, S., The
antinociceptive and antiinflammatory activities and lack of ulcerogenicity of a benzodioxin-4-one and
its analog benzoxazine as cyclic acetal-like derivatives of salicylic acid and salicylamide in mice and
rats. Indian journal of pharmacology 2002, 34 (3), 184-188.

15. Yamamoto, S.; HASHIGUCHI, S.; MIKI, S.; IGATA, Y.; WATANABE, T.; SHIRAISHI, M., Synthesis
and biological activity of novel 1, 3-Benzoxazine derivatives as K+ channel openers. Chemical and
pharmaceutical bulletin 1996, 44 (4), 734-745.

16. Schroth, W.; Borgmann, E.; Jasche, K.; Klepel, M.; Kuehne, S.; Mueller, J.; Schaedler, H., 1, 3-
oxazinone aphicides. DD273571A1: 1989.

17. Bereznak, J. F.; Marshall, E. A.; Sternberg, C. G.; Sternberg, J. A.; Sun, K.-M., Preparation of
fungicidal quinazolinones and useful intermediates. Google Patents: 2000.
18. Morris, J.; Wishka, D. G.; Lin, A. H.; Humphrey, W. R.; Wiltse, A. L.; Gammill, R. B.; Judge, T.
M.; Bisaha, S. N.; Olds, N. L.; et, a., Synthesis and biological evaluation of antiplatelet 2-
aminochromones. J. Med. Chem. 1993, 36 (14), 2026-32.

19. Urbański, T.; Radzikowski, C.; Ledochowski, Z.; Czarnocki, W., Biological activity of
benzoxazine-1, 3 derivatives, particularly against experimental sarcoma. Nature 1956, 178 (4546),
1351-1352.

20. Chylińska, J.; Urbański, T.; Mordarski, M., Dihydro-1, 3-oxazine derivatives and their
antitumor activity. Journal of medicinal chemistry 1963, 6 (5), 484-487.

21. Kuehne, M.; Konopka, E., Dihydro-1, 3-oxazines as antitumor agents. Journal of Medicinal
Chemistry 1962, 5 (2), 257-280.

22. Pritchard, K. M.; Al-Rawi, J.; Bradley, C., Synthesis, identification and antiplatelet evaluation
of 2-morpholino substituted benzoxazines. European journal of medicinal chemistry 2007, 42 (9),
1200-1210.

23. Ihmaid, S.; Al-Rawi, J.; Bradley, C., Synthesis, structural elucidation and DNA-dependant
protein kinase and antiplatelet studies of 2-amino-[5, 6, 7, 8-mono and 7, 8-di-substituted]-1, 3-
benzoxazines. European journal of medicinal chemistry 2010, 45 (11), 4934-4946.

24. Ihmaid, S. K.; Al-Rawi, J. M. A.; Bradley, C. J.; Angove, M. J.; Robertson, M. N., Synthesis,
DNA-PK inhibition, antiplatelet activity studies of 2-(N-substituted-3-aminopyridine)-substituted-1,3-
benzoxazines and DNA-PK and PI3K inhibition, homology modeling studies of 2-morpholino-(7,8-di
and 8-substituted)-1,3-benzoxazines. Eur. J. Med. Chem. 2012, 57, 85-101.

25. Ukai, T.; Hayashi, M., Untersuchung über Thiocarbonylsalicylamid (2-Thioketo-4-keto-

3, 4-dihydro-1, 3-benzoxazin). (I. Mitteil.). YAKUGAKU ZASSHI 1935, 55 (1), 8-12.

26. Grigat, E.; Putter, R.; Schneider, K.; Wedemeyer, K., Substituted benzoxazinones and a
process for their preparation. Google Patents: 1970.

27. Miyazaki, K.; Kosaka, S.; Kamimura, H., The Methylation of 3, 4-Dihydro-2H-1, 3-benzoxazine-
2-thione-4-one. Nippon kagaku zassi 1968, 89 (4), 428-430.

28. Tamura, Y.; Kawasaki, T.; Adachi, M.; Tanio, M.; Kita, Y., Thiocyanation and cyanation using a
new combined reagent of triphenylphosphine and thiocyanogen. Tetrahedron Letters 1977, 18 (50),
4417-4420.

29. Tamura, Y.; Adachi, M.; Kawasaki, T.; Kita, Y., New method for converting amines into 1, 1-
disubstituted thioureas by using a combined reagent of triphenylphosphine and thiocyanogen.
Tetrahedron Letters 1978, 19 (20), 1753-1754.

30. Iranpoor, N.; Firouzabadi, H.; Shaterian, H., Efficient one-pot thiocyanation of primary,
secondary and tertiary alcohols by in situ generation of Ph3P (SCN) 2. A modified procedure. Journal
of Chemical Research, Synopses 1999, (11), 676-677.

31. Iranpoor, N.; Firouzabadi, H.; Shaterian, H., Reaction of stable trialkylsilyl esters with Ph3P
(SCN) 2: A novel method for the preparation of acyl and aroyl isothiocyanates under neutral
condition. Synthetic communications 2002, 32 (23), 3653-3657.

32. Bedford, S. B.; Begley, M. J.; Cornwall, P.; Knight, D. W., A Brief and Mild Method for the
Generation of Benzofuran-2, 3-xylylene in Solution. Synlett 1991, 31 (09), 627-629.
33. Pritchard, K. M.; Al-Rawi, J., Reaction of Ph3P (SCN) 2 with further orthohydroxy carboxylic
acid systems, including substituted β-keto acids: synthesis of novel 2-thio-1, 3-oxazines and their
subsequent transformation with amines. Synthetic Communications® 2008, 38 (23), 4076-4096.

34. Ihmaid, S.; Al-Rawi, J.; Bradley, C.; Angove, M. J.; Robertson, M. N.; Clark, R. L., Synthesis,
structural elucidation, DNA-PK inhibition, homology modelling and anti-platelet activity of
morpholino-substituted-1, 3-naphth-oxazines. Bioorganic & medicinal chemistry 2011, 19 (13), 3983-
3994.

35. Heppell, J.; Al-Rawi, J., Functionalization of Quinazolin-4-ones Part 1: Synthesis of Novel 7-
Substituted-2-thioxo Quinazolin-4-ones from 4-Substituted-2-Aminobenzoic Acids and PPh3(SCN)2.
J. Heterocycl. Chem. 2014, 51 (1), 162-174.

36. Jasim, M.; Al-Shahiry, K. F., Synthesis of 4-Oxo-2-Thioxo-3, 4-Dihydro-2H, 1, 3-Substituted

Benzoxazine, Their Transformation with Water, Diazomethane and Amines. Asian Journal of
Chemistry 1990, 2 (4), 343.

37. Hardcastle, I. R.; Cockcroft, X.; Curtin, N. J.; El-Murr, M. D.; Leahy, J. J. J.; Stockley, M.;
Golding, B. T.; Rigoreau, L.; Richardson, C.; Smith, G. C. M.; Griffin, R. J., Discovery of Potent
Chromen-4-one Inhibitors of the DNA-Dependent Protein Kinase (DNA-PK) Using a Small-Molecule
Library Approach. J. Med. Chem. 2005, 48 (24), 7829-7846.

38. Morrison, R.; Al-Rawi, J. M.; Jennings, I. G.; Thompson, P. E.; Angove, M. J., Synthesis,
structure elucidation, DNA-PK and PI3K and anti-cancer activity of 8-and 6-aryl-substituted-1-3-
benzoxazines. European journal of medicinal chemistry 2016, 110, 326-339.

39. Morrison, R. M., Synthesis, Structural Elucidation, DNA-PK, PI3K and Antiplatelet Activity of
2-Morpholino-Substituted Chromeno-, Benzo-and Naphtho-1, 3-Oxazin-4-ones. 2015.

40. Ihmaid, S.; Ahmed, H. E.; Ali, A. A.-S.; Sherif, Y. E.; Tarazi, H. M.; Riyadh, S. M.; Zayed, M. F.;
Abulkhair, H. S.; Rateb, H. S., Rational design, synthesis, pharmacophore modeling, and docking
studies for identification of novel potent DNA-PK inhibitors. Bioorganic Chemistry 2017, 72, 234-247.

41. Morrison, R.; Belz, T.; Ihmaid, S. K.; Al-Rawi, J. M.; Angove, M. J., Dual and/or selective DNA-
PK, PI3K inhibition and isoform selectivity of some new and known 2-amino-substituted-1, 3-
benzoxazines and substituted-1, 3-naphthoxazines. Medicinal Chemistry Research 2014, 23 (11),
4680-4691.

42. Mould, E.; Berry, P.; Jamieson, D.; Hill, C.; Cano, C.; Tan, N.; Elliott, S.; Durkacz, B.; Newell, D.;
Willmore, E., Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug
activity. Biochemical pharmacology 2014, 88 (1), 58-65.

43. Meek, K.; Gupta, S.; Ramsden, D. A.; Lees‐Miller, S. P., The DNA‐dependent protein kinase:
the director at the end. Immunological reviews 2004, 200 (1), 132-141.

44. Ramiro, D.; Naegeli, H., Binding of the DNA-dependent protein kinase catalytic subunit to
Holliday junctions. Biochemical Journal 2004, 381 (1), 165-174.

45. An, J.; Huang, Y.-C.; Xu, Q.-Z.; Zhou, L.-J.; Shang, Z.-F.; Huang, B.; Wang, Y.; Liu, X.-D.; Wu, D.-
C.; Zhou, P.-K., DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in
response to DNA damage and cell cycle progression. BMC molecular biology 2010, 11 (1), 18.

46. Wong, R. H.; Chang, I.; Hudak, C. S.; Hyun, S.; Kwan, H.-Y.; Sul, H. S., A role of DNA-PK for the
metabolic gene regulation in response to insulin. Cell 2009, 136 (6), 1056-1072.
47. Ju, J.; Naura, A.; Errami, Y.; Kim, H.; Kim, J.; Beg, A. A.; Giardina, C.; Boulares, H., DNA-
DEPENDENT PROTEIN KINASE IS CRITICAL FOR VCAM-1 EXPRESSION UPON TNF TREATMENT
THROUGH PHOSPHORYLATION OF p50 NF-kappa B: A CRITICAL INVOLVEMENT IN VASCULAR AND
LUNG INFLAMMATION. The FASEB Journal 2012, 26 (1 Supplement), 1064.9-1064.9.

48. Harnor, S. J.; Brennan, A.; Cano, C., Targeting DNA-Dependent Protein Kinase for Cancer
Therapy. ChemMedChem 2017, 12 (12), 895-900.

49. Raftery, L.; Goldberg, R. M., Optimal delivery of cytotoxic chemotherapy for colon cancer.
The Cancer Journal 2010, 16 (3), 214-219.

50. Sung, P.; Klein, H., Mechanism of homologous recombination: mediators and helicases take
on regulatory functions. Nature reviews. Molecular cell biology 2006, 7 (10), 739.

51. Lieber, M. R., The mechanism of human nonhomologous DNA end joining. Journal of
Biological Chemistry 2008, 283 (1), 1-5.

52. West, S. C., Molecular views of recombination proteins and their control. Nat Rev Mol Cell
Biol 2003, 4 (6), 435-445.

53. Jackson, S. P.; Bartek, J., The DNA-damage response in human biology and disease. Nature
2009, 461 (7267), 1071-1078.

54. Davidson, D.; Amrein, L.; Panasci, L.; Aloyz, R., Small Molecules, Inhibitors of DNA-PK,
Targeting DNA Repair, and Beyond. Frontiers in Pharmacology 2013, 4, 5.

55. Hill, R.; Lee, P. W., The DNA-dependent protein kinase (DNA-PK): More than just a case of
making ends meet? Cell Cycle 2010, 9 (17), 3460-3469.

56. West, R. B.; Yaneva, M.; Lieber, M. R., Productive and nonproductive complexes of Ku and
DNA-dependent protein kinase at DNA termini. Molecular and cellular biology 1998, 18 (10), 5908-
5920.

57. Smith, G. C. M.; Jackson, S. P., The DNA-dependent protein kinase. Genes Dev. 1999, 13 (8),
916-934.

58. Shiloh, Y., ATM and related protein kinases: safeguarding genome integrity. Nature reviews.
Cancer 2003, 3 (3), 155.

59. Callén, E.; Jankovic, M.; Wong, N.; Zha, S.; Chen, H.-T.; Difilippantonio, S.; Di Virgilio, M.;
Heidkamp, G.; Alt, F. W.; Nussenzweig, A., Essential role for DNA-PKcs in DNA double-strand break
repair and apoptosis in ATM-deficient lymphocytes. Molecular cell 2009, 34 (3), 285-297.

60. Neal, J. A.; Meek, K., Choosing the right path: does DNA-PK help make the decision?
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2011, 711 (1), 73-86.

61. Stiff, T.; O’Driscoll, M.; Rief, N.; Iwabuchi, K.; Löbrich, M.; Jeggo, P. A., ATM and DNA-PK
function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer research
2004, 64 (7), 2390-2396.

62. Reitsema, T.; Klokov, D.; Banáth, J. P.; Olive, P. L., DNA-PK is responsible for enhanced
phosphorylation of histone H2AX under hypertonic conditions. DNA repair 2005, 4 (10), 1172-1181.
63. Wang, H.; Wang, M.; Wang, H.; Böcker, W.; Iliakis, G., Complex H2AX phosphorylation
patterns by multiple kinases including ATM and DNA‐PK in human cells exposed to ionizing radiation
and treated with kinase inhibitors. Journal of cellular physiology 2005, 202 (2), 492-502.

64. Mukherjee, B.; Kessinger, C.; Kobayashi, J.; Chen, B. P.; Chen, D. J.; Chatterjee, A.; Burma, S.,
DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation in mammalian cells. DNA
repair 2006, 5 (5), 575-590.

65. Koike, M.; Sugasawa, J.; Yasuda, M.; Koike, A., Tissue-specific DNA-PK-dependent H2AX
phosphorylation and γ-H2AX elimination after X-irradiation in vivo. Biochemical and biophysical
research communications 2008, 376 (1), 52-55.

66. Stronach, E. A.; Chen, M.; Maginn, E. N.; Agarwal, R.; Mills, G. B.; Wasan, H.; Gabra, H., DNA-
PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.
Neoplasia 2011, 13 (11), 1069IN31-1080IN35.

67. Azad, A.; Jackson, S.; Cullinane, C.; Natoli, A.; Neilsen, P. M.; Callen, D. F.; Maira, S.-M.; Hackl,
W.; McArthur, G. A.; Solomon, B., Inhibition of DNA-dependent protein kinase induces accelerated
senescence in irradiated human cancer cells. Molecular Cancer Research 2011, 9 (12), 1696-1707.

68. Rudolf, E.; Rudolf, K.; Cervinka, M., Camptothecin induces p53-dependent and-independent
apoptogenic signaling in melanoma cells. Apoptosis 2011, 16 (11), 1165.

69. Wei, S.; Xiong, M.; Zhan, D.-q.; Liang, B.-y.; Wang, Y.-y.; Gutmann, D. H.; Huang, Z.-y.; Chen,
X.-p., Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest
through a p53-dependent pathway. Carcinogenesis 2012, 33 (3), 538-547.

70. Chen, B. P.; Chan, D. W.; Kobayashi, J.; Burma, S.; Asaithamby, A.; Morotomi-Yano, K.;
Botvinick, E.; Qin, J.; Chen, D. J., Cell cycle dependence of DNA-dependent protein kinase
phosphorylation in response to DNA double strand breaks. Journal of Biological Chemistry 2005, 280
(15), 14709-14715.

71. Soubeyrand, S.; Pope, L.; Pakuts, B.; Haché, R. J., Threonines 2638/2647 in DNA-PK are
essential for cellular resistance to ionizing radiation. Cancer research 2003, 63 (6), 1198-1201.

72. Shinohara, E. T.; Geng, L.; Tan, J.; Chen, H.; Shir, Y.; Edwards, E.; Halbrook, J.; Kesicki, E. A.;
Kashishian, A.; Hallahan, D. E., DNA-Dependent Protein Kinase Is a Molecular Target for the
Development of Noncytotoxic Radiation–Sensitizing Drugs. Cancer research 2005, 65 (12), 4987-
4992.

73. Morris, E. P.; Rivera-Calzada, A.; da Fonseca, P. C.; Llorca, O.; Pearl, L. H.; Spagnolo, L.,
Evidence for a remodelling of DNA-PK upon autophosphorylation from electron microscopy studies.
Nucleic acids research 2011, 39 (13), 5757-5767.

74. Jackson, S. P.; Jeggo, P. A., DNA double-strand break repair and V (D) J recombination:
involvement of DNA-PK. Trends in biochemical sciences 1995, 20 (10), 412-415.

75. Davis, A. J.; So, S.; Chen, D. J., Dynamics of the PI3K-like protein kinase members ATM and
DNA-PKcs at DNA double strand breaks. Cell Cycle 2010, 9 (13), 2529-2536.

76. Neal, J. A.; Dang, V.; Douglas, P.; Wold, M. S.; Lees-Miller, S. P.; Meek, K., Inhibition of
homologous recombination by DNA-dependent protein kinase requires kinase activity, is titratable,
and is modulated by autophosphorylation. Molecular and cellular biology 2011, 31 (8), 1719-1733.
77. Kong, X.; Shen, Y.; Jiang, N.; Fei, X.; Mi, J., Emerging roles of DNA-PK besides DNA repair.
Cellular signalling 2011, 23 (8), 1273-1280.

78. Muller, C.; Christodoulopoulos, G.; Salles, B.; Panasci, L., DNA-dependent protein kinase
activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes
to nitrogen mustards. Blood 1998, 92 (7), 2213-2219.

79. Willmore, E.; Elliott, S. L.; Mainou-Fowler, T.; Summerfield, G. P.; Jackson, G. H.; O'Neill, F.;
Lowe, C.; Carter, A.; Harris, R.; Pettitt, A. R., DNA-dependent protein kinase is a therapeutic target
and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clinical Cancer Research
2008, 14 (12), 3984-3992.

80. Li, W.; Xie, C.; Yang, Z.; Chen, J.; Lu, N.-H., Abnormal DNA-PKcs and Ku 70/80 expression may
promote malignant pathological processes in gastric carcinoma. World Journal of Gastroenterology:
WJG 2013, 19 (40), 6894.

81. Abdel-Fatah, T. M. A.; Arora, A.; Moseley, P.; Coveney, C.; Perry, C.; Johnson, K.; Kent, C.;
Ball, G.; Chan, S.; Madhusudan, S., ATM, ATR and DNA-PKcs expressions correlate to adverse clinical
outcomes in epithelial ovarian cancers. BBA Clinical 2014, 2 (Supplement C), 10-17.

82. Cornell, L.; Munck, J. M.; Alsinet, C.; Villanueva, A.; Ogle, L.; Willoughby, C. E.; Televantou, D.;
Thomas, H. D.; Jackson, J.; Burt, A. D.; Newell, D.; Rose, J.; Manas, D. M.; Shapiro, G. I.; Curtin, N. J.;
Reeves, H. L., DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That
Predicts Response to Treatment and Survival. Clinical Cancer Research 2015, 21 (4), 925-933.

83. Collis, S. J.; DeWeese, T. L.; Jeggo, P. A.; Parker, A. R., The life and death of DNA-PK.
Oncogene 2005, 24 (6), 949.

84. Izzard, R. A.; Jackson, S. P.; Smith, G. C., Competitive and noncompetitive inhibition of the
DNA-dependent protein kinase. Cancer Research 1999, 59 (11), 2581-2586.

85. Boulton, S.; Kyle, S.; Yalçintepe, L.; Durkacz, B. W., Wortmannin is a potent inhibitor of DNA
double strand break but not single strand break repair in Chinese hamster ovary cells.
Carcinogenesis 1996, 17 (11), 2285-2290.

86. Maira, S.-M.; Stauffer, F.; Schnell, C.; García-Echeverría, C., PI3K inhibitors for cancer
treatment: where do we stand? Portland Press Limited: 2009.

87. Griffin, R. J.; Fontana, G.; Golding, B. T.; Guiard, S.; Hardcastle, I. R.; Leahy, J. J.; Martin, N.;
Richardson, C.; Rigoreau, L.; Stockley, M., Selective benzopyranone and pyrimido [2, 1-a] isoquinolin-
4-one inhibitors of dna-dependent protein kinase: synthesis, structure− activity studies, and
radiosensitization of a human tumor cell line in vitro. Journal of medicinal chemistry 2005, 48 (2),
569-585.

88. Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephens, L.; Hawkins, P. T.; Wymann, M. P.;
Williams, R. L., Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin,
LY294002, Quercetin, Myricetin, and Staurosporine. Molecular Cell 2000, 6 (4), 909-919.

89. Clapham, K. M.; Bardos, J.; Finlay, M. R. V.; Golding, B. T.; Griffen, E. J.; Griffin, R. J.;
Hardcastle, I. R.; Menear, K. A.; Ting, A.; Turner, P., DNA-dependent protein kinase (DNA-PK)
inhibitors: structure–activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-
binding domain. Bioorganic & medicinal chemistry letters 2011, 21 (3), 966-970.
90. Fuhrman, C. B.; Kilgore, J.; LaCoursiere, Y. D.; Lee, C. M.; Milash, B. A.; Soisson, A. P.;
Zempolich, K. A., Radiosensitization of cervical cancer cells via double-strand DNA break repair
inhibition. Gynecologic oncology 2008, 110 (1), 93-98.

91. Willmore, E.; de Caux, S.; Sunter, N. J.; Tilby, M. J.; Jackson, G. H.; Austin, C. A.; Durkacz, B.
W., A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of
topoisomerase II poisons used in the treatment of leukemia. Blood 2004, 103 (12), 4659-4665.

92. Nutley, B.; Smith, N.; Hayes, A.; Kelland, L.; Brunton, L.; Golding, B.; Smith, G.; Martin, N.;
Workman, P.; Raynaud, F., Preclinical pharmacokinetics and metabolism of a novel prototype DNA-
PK inhibitor NU7026. British journal of cancer 2005, 93 (9), 1011.

93. Hollick, J. J.; Golding, B. T.; Hardcastle, I. R.; Martin, N.; Richardson, C.; Rigoreau, L. J.; Smith,
G. C.; Griffin, R. J., 2, 6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent
protein kinase (DNA-PK). Bioorganic & medicinal chemistry letters 2003, 13 (18), 3083-3086.

94. Cano, C.; Barbeau, O. R.; Bailey, C.; Cockcroft, X.-L.; Curtin, N. J.; Duggan, H.; Frigerio, M.;
Golding, B. T.; Hardcastle, I. R.; Hummersone, M. G., DNA-dependent protein kinase (DNA-PK)
inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates
for the chromen-4-one chemotype. Journal of medicinal chemistry 2010, 53 (24), 8498-8507.

95. Veuger, S. J.; Curtin, N. J.; Richardson, C. J.; Smith, G. C.; Durkacz, B. W., Radiosensitization
and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase
and poly (ADP-ribose) polymerase-1. Cancer research 2003, 63 (18), 6008-6015.

96. Hollick, J. J.; Rigoreau, L. J.; Cano-Soumillac, C.; Cockcroft, X.; Curtin, N. J.; Frigerio, M.;
Golding, B. T.; Guiard, S.; Hardcastle, I. R.; Hickson, I., Pyranone, thiopyranone, and pyridone
inhibitors of phosphatidylinositol 3-kinase related kinases. Structure− activity relationships for DNA-
dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of
the ataxia telangiectasia mutated kinase. Journal of medicinal chemistry 2007, 50 (8), 1958-1972.

97. Leahy, J. J. J.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.; Richardson, C.; Rigoreau, L.; Smith,
G. C. M., Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK)
inhibitor (NU7441) by screening of chromenone libraries. Bioorg. Med. Chem. Lett. 2004, 14 (24),
6083-6087.

98. Clapham, K. M.; Rennison, T.; Jones, G.; Craven, F.; Bardos, J.; Golding, B. T.; Griffin, R. J.;
Haggerty, K.; Hardcastle, I. R.; Thommes, P., Potent enantioselective inhibition of DNA-dependent
protein kinase (DNA-PK) by atropisomeric chromenone derivatives. Organic & biomolecular
chemistry 2012, 10 (33), 6747-6757.

99. Tavecchio, M.; Munck, J. M.; Cano, C.; Newell, D. R.; Curtin, N. J., Further characterisation of
the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous
recombination. Cancer chemotherapy and pharmacology 2012, 69 (1), 155-164.

100. Zhao, Y.; Thomas, H. D.; Batey, M. A.; Cowell, I. G.; Richardson, C. J.; Griffin, R. J.; Calvert, A.
H.; Newell, D. R.; Smith, G. C.; Curtin, N. J., Preclinical evaluation of a potent novel DNA-dependent
protein kinase inhibitor NU7441. Cancer research 2006, 66 (10), 5354-5362.

101. Kashishian, A.; Douangpanya, H.; Clark, D.; Schlachter, S. T.; Eary, C. T.; Schiro, J. G.; Huang,
H.; Burgess, L. E.; Kesicki, E. A.; Halbrook, J., DNA-dependent protein kinase inhibitors as drug
candidates for the treatment of cancer. Molecular cancer therapeutics 2003, 2 (12), 1257-1264.
102. Zenke, F. T.; Zimmermann, A.; Sirrenberg, C.; Dahmen, H.; Vassilev, L.; Pehl, U.; Fuchss, T.;
Blaukat, A., M3814, a novel investigational DNA-PK inhibitor: enhancing the effect of fractionated
radiotherapy leading to complete regression of tumors in mice. AACR: 2016.

103. Cano, C. l.; Saravanan, K.; Bailey, C.; Bardos, J.; Curtin, N. J.; Frigerio, M.; Golding, B. T.;
Hardcastle, I. R.; Hummersone, M. G.; Menear, K. A., 1-Substituted (Dibenzo [b, d] thiophen-4-yl)-2-
morpholino-4 H-chromen-4-ones Endowed with Dual DNA-PK/PI3-K Inhibitory Activity. Journal of
medicinal chemistry 2013, 56 (16), 6386-6401.

104. Munck, J. M.; Batey, M. A.; Zhao, Y.; Jenkins, H.; Richardson, C. J.; Cano, C.; Tavecchio, M.;
Barbeau, J.; Bardos, J.; Cornell, L.; Griffin, R. J.; Menear, K.; Slade, A.; Thommes, P.; Martin, N. M. B.;
Newell, D. R.; Smith, G. C. M.; Curtin, N. J., Chemosensitization of Cancer Cells by KU-0060648, a Dual
Inhibitor of DNA-PK and PI-3K. Molecular Cancer Therapeutics 2012, 11 (8), 1789-1798.

105. Murr, M. D.-E.; Cano, C.; Golding, B. T.; Hardcastle, I. R.; Hummersome, M.; Frigerio, M.;
Curtin, N. J.; Menear, K.; Richardson, C.; Smith, G. C. M.; Griffin, R. J., 8-Biarylchromen-4-one
inhibitors of the DNA-dependent protein kinase (DNA-PK). Bioorganic & Medicinal Chemistry Letters
2008, 18 (17), 4885-4890.

106. Take, Y.; Kumano, M.; Teraoka, H.; Nishimura, S.; Okuyama, A., DNA-dependent protein
kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53
induced by adriamycin. Biochemical and biophysical research communications 1996, 221 (2), 207-
212.

107. Durant, S.; Karran, P., Vanillins—a novel family of DNA‐PK inhibitors. Nucleic acids research
2003, 31 (19), 5501-5512.

108. Knight, Z. A.; Chiang, G. G.; Alaimo, P. J.; Kenski, D. M.; Ho, C. B.; Coan, K.; Abraham, R. T.;
Shokat, K. M., Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold.
Bioorganic & Medicinal Chemistry 2004, 12 (17), 4749-4759.

109. Ismail, I. H.; Martensson, S.; Moshinsky, D.; Rice, A.; Tang, C.; Howlett, A.; McMahon, G.;
Hammarsten, O., SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break
repair resulting in ionizing radiation sensitization. Oncogene 2003, 23 (4), 873-882.

110. Boucher, D.; Hoover, R.; Wang, Y.; Gu, Y.; Newsome, D.; Ford, P.; Moody, C.; Damagnez, V.;
Arimoto, R.; Hillier, S., Potent radiation enhancement with VX-984, a selective DNA-PKcs inhibitor for
the treatment of NSCLC. AACR: 2016.

111. Damstrup, L.; Zimmerman, A.; Sirrenberg, C.; Zenke, F.; Vassilev, L., M3814, a DNA-
dependent Protein Kinase Inhibitor (DNA-PKi), Potentiates the Effect of Ionizing Radiation (IR) in
Xenotransplanted Tumors in Nude Mice. International Journal of Radiation
Oncology*Biology*Physics 2016, 94 (4), 940-941.

112. Radhamani, S.; Bradley, C.; Meehan-Andrews, T.; Ihmaid, S. K.; Al-Rawi, J., Radiosensitizing
activity of a novel Benzoxazine through the promotion of apoptosis and inhibition of DNA repair.
Invest. New Drugs 2014, 32 (3), 424-435.

113. Kong, D.; Yaguchi, S.-i.; Yamori, T., Effect of ZSTK474, a novel phosphatidylinositol 3-kinase
inhibitor, on DNA-dependent protein kinase. Biological and Pharmaceutical Bulletin 2009, 32 (2),
297-300.
114. Lee, C. M.; Fuhrman, C. B.; Planelles, V.; Peltier, M. R.; Gaffney, D. K.; Soisson, A. P.; Dodson,
M. K.; Tolley, H. D.; Green, C. L.; Zempolich, K. A., Phosphatidylinositol 3-kinase inhibition by
LY294002 radiosensitizes human cervical cancer cell lines. Clinical cancer research 2006, 12 (1), 250-
256.

115. Morrison, R.; Zheng, Z.; Jennings, I. G.; Thompson, P. E.; Al-Rawi, J. M., Synthesis of linear
and angular aryl-morpholino-naphth-oxazines, their DNA-PK, PI3K, PDE3A and antiplatelet activity.
Bioorganic & Medicinal Chemistry Letters 2016, 26 (22), 5534-5538.

116. Sibanda, B. L.; Chirgadze, D. Y.; Blundell, T. L., Crystal structure of DNA-PKcs reveals a large
open-ring cradle comprised of HEAT repeats. Nature 2010, 463 (7277), 118.

117. Cantley, L. C., The phosphoinositide 3-kinase pathway. Science 2002, 296 (5573), 1655-1657.

118. Burris, H. A., Overcoming acquired resistance to anticancer therapy: focus on the
PI3K/AKT/mTOR pathway. Cancer chemotherapy and pharmacology 2013, 71 (4), 829-842.

119. Osaki, M.; Oshimura, M. a.; Ito, H., PI3K-Akt pathway: its functions and alterations in human
cancer. Apoptosis 2004, 9 (6), 667-676.

120. Akinleye, A.; Chen, Y.; Mukhi, N.; Song, Y.; Liu, D., Ibrutinib and novel BTK inhibitors in clinical
development. Journal of hematology & oncology 2013, 6 (1), 59.

121. Hu, C.; Huang, L.; Gest, C.; Xi, X.; Janin, A.; Soria, C.; Li, H.; Lu, H., Opposite regulation by
PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity
and invasiveness in MDA-MB-231 cells. Journal of hematology & oncology 2012, 5 (1), 16.

122. Courtney, K. D.; Corcoran, R. B.; Engelman, J. A., The PI3K pathway as drug target in human
cancer. Journal of clinical oncology 2010, 28 (6), 1075-1083.

123. Vanhaesebroeck, B.; Leevers, S. J.; Panayotou, G.; Waterfield, M. D., Phosphoinositide 3-
kinases: a conserved family of signal transducers. Trends in biochemical sciences 1997, 22 (7), 267-
272.

124. Katso, R.; Okkenhaug, K.; Ahmadi, K.; White, S.; Timms, J.; Waterfield, M. D., Cellular
function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and
cancer. Annual review of cell and developmental biology 2001, 17 (1), 615-675.

125. Engelman, J. A.; Luo, J.; Cantley, L. C., The evolution of phosphatidylinositol 3-kinases as
regulators of growth and metabolism. Nature reviews. Genetics 2006, 7 (8), 606.

126. Clément, S.; Krause, U.; Desmedt, F.; Tanti, J.-F., The lipid phosphatase SHIP2 controls insulin
sensitivity. Nature 2001, 409 (6816), 92.

127. Bitting, R. L.; Armstrong, A. J., Targeting the PI3K/Akt/mTOR pathway in castration-resistant
prostate cancer. Endocrine-related cancer 2013, 20 (3), R83-R99.

128. Patel, S., Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway.
Current oncology reports 2013, 15 (4), 386-395.

129. Arteaga, C. L., Clinical development of phosphatidylinositol-3 kinase pathway inhibitors. In

Phosphoinositide 3-kinase in Health and Disease, Springer: 2010; pp 189-208.

130. Liu, P.; Cheng, H.; Roberts, T. M.; Zhao, J. J., Targeting the phosphoinositide 3-kinase
pathway in cancer. Nature reviews Drug discovery 2009, 8 (8), 627-644.
131. Bénistant, C.; Chapuis, H.; Roche, S., A specific function for phosphatidylinositol 3-kinase
[alpha](p85 [alpha]-p110 [alpha]) in cell survival and for phosphatidylinositol 3-kinase [beta](p85
[alpha]-p110 [beta]) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 2000, 19
(44), 5083.

132. Parsons, D. W.; Jones, S.; Zhang, X.; Lin, J. C.-H.; Leary, R. J.; Angenendt, P.; Mankoo, P.;
Carter, H.; Siu, I.-M.; Gallia, G. L., An integrated genomic analysis of human glioblastoma multiforme.
Science 2008, 321 (5897), 1807-1812.

133. Martini, M.; Ciraolo, E.; Gulluni, F.; Hirsch, E., Targeting PI3K in cancer: any good news?
Frontiers in oncology 2013, 3.

134. Liu, Y.; Shreder, K. R.; Gai, W.; Corral, S.; Ferris, D. K.; Rosenblum, J. S., Wortmannin, a widely
used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase.
Chemistry & biology 2005, 12 (1), 99-107.

135. Lannutti, B. J.; Meadows, S. A.; Herman, S. E.; Kashishian, A.; Steiner, B.; Johnson, A. J.; Byrd,
J. C.; Tyner, J. W.; Loriaux, M. M.; Deininger, M., CAL-101, a p110δ selective phosphatidylinositol-3-
kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
Blood 2011, 117 (2), 591-594.

136. Benson, D. M.; Kahl, B. S.; Furman, R. R.; Brown, J. R.; Wagner-Johnston, N. D.; Coutre, S. E.;
Spurgeon, S. E. F.; Byrd, J. C.; Leonard, J.; Peterman, S., Final results of a phase I study of idelalisib, a
selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma
(iNHL). American Society of Clinical Oncology: 2013.

137. Hoellenriegel, J.; Meadows, S. A.; Sivina, M.; Wierda, W. G.; Kantarjian, H.; Keating, M. J.;
Giese, N.; O'Brien, S.; Yu, A.; Miller, L. L., The phosphoinositide 3′-kinase delta inhibitor, CAL-101,
inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood
2011, 118 (13), 3603-3612.

138. Ikeda, H.; Hideshima, T.; Fulciniti, M.; Perrone, G.; Miura, N.; Yasui, H.; Okawa, Y.; Kiziltepe,
T.; Santo, L.; Vallet, S., PI3K/p110δ is a novel therapeutic target in multiple myeloma. Blood 2010,
116 (9), 1460-1468.

139. Herman, S. E.; Gordon, A. L.; Wagner, A. J.; Heerema, N. A.; Zhao, W.; Flynn, J. M.; Jones, J.;
Andritsos, L.; Puri, K. D.; Lannutti, B. J., Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows
promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic
cellular survival signals. Blood 2010, 116 (12), 2078-2088.

140. Furman, R. R.; Byrd, J. C.; Brown, J. R.; Coutre, S. E.; Benson, D. M.; Wagner-Johnston, N. D.;
Flinn, I. W.; Kahl, B. S.; Spurgeon, S. E.; Lannutti, B., CAL-101, an isoform-selective inhibitor of
phosphatidylinositol 3-kinase P110δ, demonstrates clinical activity and pharmacodynamic effects in
patients with relapsed or refractory chronic lymphocytic leukemia. Am Soc Hematology: 2010.

141. Brown, J. R.; Furman, R. R.; Flinn, I.; Coutre, S. E.; Wagner-Johnston, N. D.; Kahl, B. S.;
Spurgeon, S. E. F.; Benson, D. M.; Peterman, S.; Johnson, D. M., Final results of a phase I study of
idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL.
American Society of Clinical Oncology: 2013.

142. Lemery, S. J.; Zhang, J. Z.; Rothmann, M. D.; Yang, J.; Earp, J. C.; Zhao, H.; McDougal, A.;
Pilaro, A.; Chiang, R.; Gootenberg, J., US Food and Drug Administration approval: ofatumumab for
the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and
alemtuzumab. Clinical Cancer Research 2010, clincanres. 0570. subyr.

143. Coutre, S.; Byrd, J.; Furman, R.; Brown, J.; Benson, D.; Wagner-Johnston, N.; Flinn, I.; Kahl, B.;
Spurgeon, S.; Lannutti, B., Phase I study of CAL-101, an isoform-selective inhibitor of
phosphatidylinositol 3‐kinase P110d, in patients with previously treated chronic lymphocytic
leukemia. Journal of Clinical Oncology 2011, 29 (15_suppl), 6631-6631.

144. Bendell, J. C.; Rodon, J.; Burris, H. A.; de Jonge, M.; Verweij, J.; Birle, D.; Demanse, D.; De
Buck, S. S.; Ru, Q. C.; Peters, M., Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K
inhibitor, in patients with advanced solid tumors. Journal of clinical oncology 2011, 30 (3), 282-290.

145. Von Hoff, D.; LoRusso, P.; Demetri, G.; Weiss, G.; Shapiro, G.; Ramanathan, R.; Ware, J.; Raja,
R.; Jin, J.; Levy, G., A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor,
administered QD or BID in patients with advanced or metastatic solid tumors. Journal of Clinical
Oncology 2011, 29 (15_suppl), 3052-3052.

146. Jimeno, A.; Herbst, R.; Falchook, G.; Messersmith, W.; Hecker, S.; Peterson, S.; Hausman, D.;
Kurzrock, R.; Eckhardt, S.; Hong, D., Final results from a phase I, dose-escalation study of PX-866, an
irreversible, pan-isoform inhibitor of PI3 kinase. Journal of Clinical Oncology 2010, 28 (15_suppl),
3089-3089.

147. Juric, D.; Krop, I.; Ramanathan, R. K.; Xiao, J.; Sanabria, S.; Wilson, T. R.; Choi, Y.; Parmar, H.;
Hsu, J.; Baselga, J., Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-
in-human phase Ia dose escalation study. AACR: 2013.

148. Patnaik, A.; Ramanathan, R. K.; Appleman, L. J.; Tolcher, A. W.; Mountz, J. M.; Beerham, M.;
Weiss, G. J.; Rasco, D. W.; Lotze, M. T.; Toledo, F. G., Phase I study of intravenous PI3K inhibitor bay
80–6946: Preliminary activity in patients with relapsed non-Hodgkin lymphoma (NHL) treated in an
MTD expansion cohort. Am Soc Hematology: 2012.

149. Flinn, I. W.; Horwitz, S. M.; Patel, M.; Younes, A.; Porter, J. R.; Sweeney, J.; Allen, K.; Kelly, P.;
Kahl, B. S., Clinical safety and activity in a Phase 1 trial of IPI-145, a potent inhibitor of
phosphoinositide-3-kinase-δ, γ, in patients with advanced hematologic malignancies. Am Soc
Hematology: 2012.

150. Arkenau, H.-T.; Jones, S. F.; Kurkjian, C.; Infante, J. R.; Pant, S.; Burris, H. A.; Moore, K. N.;
McMeekin, D. S.; Greco, F. A.; Ramsey, S., The PI3K/mTOR inhibitor BEZ235 given twice daily for the
treatment of patients (pts) with advanced solid tumors. American Society of Clinical Oncology: 2012.

151. Juric, D.; Rodon, J.; Gonzalez-Angulo, A.; Burris, H.; Bendell, J.; Berlin, J.; Middleton, M.;
Bootle, D.; Boehm, M.; Schmitt, A., BYL719, a next generation PI3K alpha specific inhibitor:
Preliminary safety. PK, and efficacy results from the first-in-human study 2012.

152. Markman, B.; Tabernero, J.; Krop, I.; Shapiro, G.; Siu, L.; Chen, L.; Mita, M.; Melendez Cuero,
M.; Stutvoet, S.; Birle, D., Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral
phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.
Annals of oncology 2012, 23 (9), 2399-2408.

153. Millham, R.; Houk, B.; Borzillo, G.; LoRusso, P.; Marburg, L.; Britten, C.; Wainberg, Z.; Adjei,
A.; Dy, G. In First-in-patient study of PF-049691502, a small molecule intravenous dual inhibitor of
PI3K and mTOR in patients with advanced cancer: update on safety, efficacy, and pharmacology,
AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics (Vol. 10,
pp. Abstr nr B163), Molecular Cancer Therapeutics San Francisco, CA: 2011.

154. Funke, R. P.; Zhu, J.; Meng, R. D.; Yan, Y.; Musib, L. C.; Talluto, C. C.; Patel, P. H., A phase Ib/II
study testing the safety and efficacy of combined inhibition of the AKT/PI3K and AR signaling
pathways in castration-resistant prostate cancer: GDC-0068 or GDC-0980 with abiraterone acetate
versus abiraterone acetate. American Society of Clinical Oncology: 2012.

155. Munster, P.; van der Noll, R.; Voest, E.; Dees, E.; Tan, A.; Specht, J.; Falchook, G.; Daud, A.;
Lolkema, M.; Grilley-Olson, J., Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458
(GSK458) in patients with advanced solid tumors (study P3K112826). Journal of Clinical Oncology
2011, 29 (15_suppl), 3018-3018.

156. Millham, R.; Houk, B.; Borzillo, G.; Tabernero, J.; Bell-McGuinn, K.; Bendell, J.; Molina, J.;
Kwak, E.; Shapiro, G., Abstract A167: First-in-patient study of PF-05212384, a small molecule
intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety,
efficacy, and pharmacology. AACR: 2011.

157. Nghiemphu, P.; Omuro, A. M.; Cloughesy, T.; Mellinghoff, I. K.; Norden, A. D.; Nguyen, L.;
Rajangam, K.; Wen, P. Y., A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel
PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly
diagnosed malignant glioma. Journal of Clinical Oncology 2010, 28 (15_suppl), 3085-3085.

158. Edelman, G.; Bedell, C.; Shapiro, G.; Pandya, S.; Kwak, E.; Scheffold, C.; Nguyen, L.; Laird, A.;
Baselga, J.; Rodon, J., A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor
administered orally to patients with advanced malignancies. J Clin Oncol 2010, 28 (15), A3004.

159. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F., A specific inhibitor of phosphatidylinositol
3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 1994, 269
(7), 5241-8.

160. Al-Rawi, S.; Meehan-Andrews, T.; Bradley, C.; Al-Rawi, J., Novel benzoxazines as inhibitors of
angiogenesis. Invest. New Drugs 2015, 33 (1), 45-52.

161. Shuttleworth, S. J.; Silva, F. A.; Cecil, A. R. L.; Hill, T. J. Preparation of benzo[1,3]oxazinone
derivatives as PI3 kinase inhibitors. WO2011012883A1, 2011.